Manufacturing hiccup resolved Dr Reddy's Laboratories announced that the scale‑up difficulty affecting the active pharmaceutical ingredient (API) for its generic semaglutide has been remedied. Management confirmed that formulation batches are now being produced, clearing the path for a market re‑entry.
November relaunch plan The firm expects to restart supplies in November, covering ten international markets. CEO **Erez Israeli** projected shipments of **6‑7 million units** for the combined third and fourth quarters, with **Canada delivering the bulk of those units**. No fresh regulatory clearance is required for the Canadian market, as the earlier voluntary withdrawal was purely a manufacturing decision.
Financial impact In the June quarter, Dr Reddy's booked a **Rs 240 crore provision** to cover inventory and costs linked to the API issue, which dented Q1 earnings. CFO **M.V. Narasimham** said the company does not anticipate similar profit‑and‑loss hits moving forward, given the resolved production bottleneck.
Market footprint and future expansion The Hyderabad‑based company already holds semaglutide approvals in ten countries, including India and Canada, and eight approvals across emerging markets in Latin America, Africa and the Middle East. A recent approval in **Chile** makes Dr Reddy's the first generic entrant there. Management signalled that launches in **Europe and the United States** are part of a longer‑term roadmap.
Indian market continuity While the API issue unfolded, Dr Reddy's sustained its Indian presence through an alternative supply arrangement, continuing to market semaglutide for diabetes and weight‑management indications.
Outlook The company views semaglutide as a core growth driver globally. With demand described as “very strong” and the market still under‑served by generics, Dr Reddy's expects the November restart to unlock a multi‑year opportunity.
--- *The information above is based on statements made by Dr Reddy's management during a media call.*